[Persistent pulmonary hypertension of newborn. The PFC syndrome].
Persistent pulmonary hypertension of the newborn (PPHN), initially described by Gersony et al as persistent foetal circulation (PFC syndrome), results from a flawed transition from foetal to extrauterine pulmonary circulation. It is characterised by the maintenance of a high pulmonary vascular resistance and right-to-left shunting through the ductus arteriosus and foramen ovale. Infants with a wide variety of underlying clinical conditions develop PPHN. According to Rudolph three main anatomic types of PPHN can be identified: normal pulmonary vascular development increased pulmonary vascular smooth muscle development decreased cross-sectional area of pulmonary vascular bed. It is important to realize that several pathophysiologic mechanisms may coexist and interact. Besides metabolic and respiratory acidosis, hypercapnia and hypoxaemia some other factors induce pulmonary vasoconstriction. Thromboxane, leukotrienes and prostaglandins play a decisive role. Since PPHN can be associated with a broad spectrum of clinical conditions, a specific clinical picture is lacking. The baby is usually term or post-term, cyanotic immediately after birth or some hours later. Birth asphyxia, hyperviscosity, sepsis and aspiration of meconium have been recognized as predisposing factors. The diagnosis can be confirmed by echocardiography. Contrast echo will indicate right-to-left shunting with normal anatomy. Currently hyperventilation, tolazolin, chlorpromazin and dopamine/dobutamine have been advocated as central foci for clinical therapy. Recently prostacyclin was introduced as a specific pulmonary vasodilatator.(ABSTRACT TRUNCATED AT 250 WORDS)
Hörnchen
H
H
Kinderklinik, Medizinischen Fakultät, RWTH Aachen.
Merz
U
U
Wicher
W
W
Mühler
E
E
D004452:Echocardiography; D015199:Extracorporeal Membrane Oxygenation; D006612:High-Frequency Ventilation / Q000379:methods; D006801:Humans; D007231:Infant, Newborn; D010547:Persistent Fetal Circulation Syndrome / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D011453:Prostaglandins / Q000627:therapeutic use; D011652:Pulmonary Circulation; D014655:Vascular Resistance; D014665:Vasodilator Agents / Q000627:therapeutic use
D011453:Prostaglandins; D014665:Vasodilator Agents
Die persistierende pulmonale Hypertension des Neugeborenen. Das "PFC-Syndrom".